Cell News and Research

RSS

New personalized therapy fools cancer cells into killing themselves

A Wayne State University School of Medicine physician-researcher has developed a personalized therapy to treat a wide range of cancers. The treatment is based on a naturally occurring human enzyme that has been genetically modified to fool cancer cells into killing themselves.

1 Mar 2011

Cellectis launches new TALEN Access tool for genome customization

Cellectis bioresearch, a specialist in genome customization and subsidiary of Cellectis, has today launched TALEN Access, the first fee-for-service custom TALEN.

1 Mar 2011

Positive preliminary data from SB-728-902 Phase 1 trial against HIV/AIDS presented at 18th CROI

Sangamo BioSciences, Inc. announced today the presentation of positive preliminary clinical data from its Phase 1 trial.

1 Mar 2011

Dermatan sulfate holds potential as an additional biomarker for Sanfilippo disease

Sanfilippo disease is a rare disorder caused by the failure of enzymes to break down specific kinds of complex carbohydrates, resulting in their accumulation in cells and often severe physical and neurological problems - and sometimes early death.

1 Mar 2011

Protein pathway may hold a clue for understanding Parkinson's disease

A protein pathway that may hold the secret to understanding Parkinson's disease has been discovered and explained by Iowa State University researchers.

1 Mar 2011

Research uncovers new details about protein interactions in retina

Science fiction novelist and scholar Issac Asimov once said, "The most exciting phrase to hear in science, the one that heralds new discoveries, is not 'Eureka!' but 'That's funny.' " This recently rang true for an international team of researchers when they observed something they did not expect.

1 Mar 2011

Scientists fuse human fat stem cells with rat cardiomyocytes to form new muscles

If Dr. Doolittle is famous for talking to animals, then here's a story that might make him hold his tongue: According to new research published online in The FASEB Journal, scientists have successfully fused human stem cells derived from subcutaneous adipose tissue with muscle cells from rat hearts.

1 Mar 2011

PAH closely related to bone marrow abnormalities

Results from a study published in Blood, the Journal of the American Society of Hematology reveal a close relationship between pulmonary arterial hypertension (PAH)-exceedingly high blood pressure in the arteries carrying blood from the heart to the lungs-and abnormalities of the blood-forming cells in the bone marrow (known as myeloid abnormalities).

1 Mar 2011

CellSeed, LA BioMed enter two-year research agreement to study core technology in regenerative medicine

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and CellSeed Inc., a Japanese biotechnology firm, have entered into a two-year research agreement to study CellSeed's proprietary core technology in regenerative medicine, "Cell Sheet Engineering," LA BioMed President and CEO David I. Meyer, PhD, announced today.

28 Feb 2011

TCD announces first patient treated in its TCD-717 Phase I trial

Traslational Cancer Drugs Pharma, S.L. (“TCD”) announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The Principal Investigators are Dr. Julie Brahmer at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital in Baltimore; and Dr. Patricia LoRusso at the Barbara Ann Karmanos Cancer Institute in Detroit.

28 Feb 2011

Cryo-Cell fiscal 2010 net income increases to $3.4 million

Cryo-Cell International, Inc., one of the world's largest and most established family cord blood banks and an industry leader of innovative stem cell solutions, today announced results for its fiscal year 2010.

28 Feb 2011

BrainStorm raises $3.6 million through private placement financing

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, announced today that it has entered into securities purchase agreements with certain institutional and other investors in connection with a private placement financing in reliance upon Regulation S. BrainStorm received gross proceeds of approximately $3.6 million resulting from the sale of shares at a purchase price of $0.28 per share at the closing of the transaction.

28 Feb 2011

Tenofovir gel may help reduce risk of HIV from anal sex

A gel developed to protect against HIV during vaginal sex produced a strong antiviral effect when used in the rectum, according to an early-phase study presented today at the 18th Conference on Retroviruses and Opportunistic Infections (CROI). The results, based on rectal tissue biopsies sampled from HIV-negative men and women who used the product daily for one week, provide the first-ever evidence that tenofovir gel could help reduce the risk of HIV from anal sex, even though the vaginal gel formulation may not be optimal for rectal use.

28 Feb 2011

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Regeneron Pharmaceuticals, Inc. announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) met the primary and all secondary study endpoints. The primary endpoint was the number of gout flares per patient over the 16-week treatment period.

28 Feb 2011

Celgene's ISTODAX sNDA granted FDA Priority Review classification for progressive/relapsed PTCL

Celgene Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review classification to its Supplemental New Drug Application (sNDA) regarding ISTODAX (romidepsin) for injection for the treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy.

28 Feb 2011

Acasti receives conditional approval for listing of class A shares on TSX-Venture

Neptune Technologies & Bioressources Inc. and Acasti Pharma, a Neptune subsidiary, announces that Acasti has received conditional approval for the listing of its class A common shares on the TSX Venture Exchange under the ticker symbol APO.

28 Feb 2011

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Seattle Genetics, Inc. announced today that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for the use of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma.

28 Feb 2011

p53 gene blocks EMT essential to cancer metastasis

Like a bounty hunter returning escapees to custody, a cancer-fighting gene converts organ cells that change into highly mobile stem cells back to their original, stationary state, researchers report online at Nature Cell Biology.

28 Feb 2011

Global Genes Project, 46NYC introduce t-shirts to create awareness about lack of drug treatments for rare disease

Wear That You Care. Today is Rare Disease Day and 46NYC is helping raise awareness for an important cause – this time the drug development crisis facing the rare disease patient community worldwide.

28 Feb 2011

New horse stem cell discovery aids in preclinical model development for human degenerative diseases

In a world first, pluripotent stem cells have been generated from horses by a team of researchers led by Dr. Andras Nagy at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital and Dr. Lawrence Smith at the University of Montreal's Faculty of Veterinary Science.

28 Feb 2011

Cell News and Research

New personalized therapy fools cancer cells into killing themselves

Cellectis launches new TALEN Access tool for genome customization

Positive preliminary data from SB-728-902 Phase 1 trial against HIV/AIDS presented at 18th CROI

Dermatan sulfate holds potential as an additional biomarker for Sanfilippo disease

Protein pathway may hold a clue for understanding Parkinson's disease

Research uncovers new details about protein interactions in retina

Scientists fuse human fat stem cells with rat cardiomyocytes to form new muscles

PAH closely related to bone marrow abnormalities

CellSeed, LA BioMed enter two-year research agreement to study core technology in regenerative medicine

TCD announces first patient treated in its TCD-717 Phase I trial

Cryo-Cell fiscal 2010 net income increases to $3.4 million

BrainStorm raises $3.6 million through private placement financing

Tenofovir gel may help reduce risk of HIV from anal sex

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Celgene's ISTODAX sNDA granted FDA Priority Review classification for progressive/relapsed PTCL

Acasti receives conditional approval for listing of class A shares on TSX-Venture

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

p53 gene blocks EMT essential to cancer metastasis

Global Genes Project, 46NYC introduce t-shirts to create awareness about lack of drug treatments for rare disease

New horse stem cell discovery aids in preclinical model development for human degenerative diseases

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News